Regulated information: Disclosure of a transparency notification from BlackRock, Inc.

Regulated information

Nazareth (Belgium)/Rotterdam (The Netherlands), 16 October 2026 – 6 PM CET

Disclosure of a transparency notification from BlackRock, Inc.

Pursuant to the Belgian act of 2 May 2007 on the disclosure of major shareholdings in listed companies, Fagron received a transparency notification from BlackRock, Inc., dated 13 October 2026.

Notification from BlackRock, Inc.

The total number of 2,015,779 shares corresponds to the same number of voting rights.

The total number of 166,184 equivalent financial instruments corresponds to the same number of voting rights.

Further information

Ignacio Artola

Global Head of Investor Relations

investors@fagron.com

About Fagron

Fagron is the leading global company active in pharmaceutical compounding, focusing on delivering personalized medicine to hospitals, pharmacies, clinics, and patients in more than 38 countries around the world.

The Belgian company Fagron NV is based in Nazareth and is listed on Euronext Brussels and Euronext Amsterdam under the ticker symbol ‘FAGR’. Fagron’s operational activities are managed through the Dutch company Fagron BV with head office in Rotterdam.

Important information regarding forward-looking statements

Certain statements in this press release may be deemed to be forward-looking. Such forward-looking statements are based on current expectations and are influenced by various risks and uncertainties. Consequently, Fagron cannot provide any guarantee that such forward-looking statements will, in fact, materialize and cannot accept any obligation to update or revise any forward-looking statement as a result of new information, future events or for any other reason.

In the event of differences between the English translation and the Dutch original of this press release, the latter prevails.

Attachment